Table 3.

Results from sub group analysis on treatment success

Variables	# of Studies	Point Estimate	95 % CI
Start year of study
2000 or later [6, 11, 14, 30, 33–35, 38–42]	12	0.64	0.54	0.74
1999 or earlier [31, 32, 36, 37]	4	0.60	0.44	0.77
Quality of study
Very Low [6, 11, 14, 30–35, 39, 41]	11	0.65	0.54	0.75
Low [36–38, 40, 42]	5	0.59	0.44	0.74
Adverse Events
< 50 % [34–36]	3	0.76	0.70	0.82
> 50 % [6, 31–33, 38, 40–42]	8	0.63	0.52	0.73
Type of treated patients
New cases and previously treated [6, 30–32, 34–37, 39, 41, 42]	11	0.61	0.52	0.71
Previously treated patients [11, 33, 38, 40]	4	0.66	0.53	0.78
HIV co-infected patientsa
Yes [6, 11, 30, 32, 35, 37–40, 42]	10	0.57	0.49	0.64
No [14, 30, 33–35]	6	0.72	0.65	0.79
Patient type
MDR [6, 11, 14, 31, 33–36, 39–42]	12	0.67	0.56	0.78
MDR and XDR [30, 32, 37]	3	0.51	0.48	0.55
XDR [38]	1	0.48	0.30	0.66
DOTS-plus Provider
Healthcare workers [30–32, 36, 38, 40–42]	8	0.59	0.48	0.69
Home care support teams & Family [6, 11]	2	0.78	0.60	0.95
Home care support teams [14]	1	0.71	0.62	0.80
Healthcare workers & Family [33, 35]	2	0.72	0.61	0.83
Family [34]	1	0.79	0.72	0.86
Drug Regimen Model
Standardized [6, 11, 30, 33–36, 39, 42]	9	0.66	0.53	0.79
Individualized [31, 32, 37, 38, 40, 41]	6	0.57	0.51	0.62
DOTS-plus Location
Health center [14, 30, 33, 34]	4	0.70	0.56	0.84
Patient home [6]	1	0.84	0.76	0.92
Patient home and Health center [11, 31, 32, 35]	4	0.61	0.53	0.68
Hospital [36–42]	7	0.57	0.44	0.69
Duration of DOTS-plusa
Throughout therapy [6, 11, 14, 30, 33–36, 40]	9	0.72	0.65	0.79
Partial observation [31, 32, 38, 39, 42]	5	0.50	0.43	0.57
Length of treatment (months)a
< 18 [32, 42]	2	0.48	0.42	0.55
18 & above [6, 11, 14, 30–35, 37, 39–41]	12	0.65	0.56	0.74
Drugs in regimena
5 [11, 30–32, 34, 35, 37–39, 41, 42]	11	0.57	0.49	0.64
> 5 [6, 33]	2	0.82	0.76	0.89

^aNon-overlapping 95 % CI